This underscores the enhanced discriminatory power gained by integrating multiomic biomarker data, especially compared with previously observed performance for CA125 alone of just 76% in distinguishing early-stage ovarian cancer from benign tumors (33). Here, MUC16 is linked to ovarian cancer.